Recentresearchhas recognised newpopulations of non-hematopoïetic cellsinthe blood.One of these,circulating endothelial cells (CECs),often defined by the expression of membraneglycoprotein CD146, arer arelyf oundi nt he blood in health, but raisedn umbers arep resent in aw idev ariety of human conditions, including inflammatory,i mmune,i nfectious, neoplastic and cardiovascular disease,and seem likelyt ob ee vidence of profound vascular insult.An additional population areendothelial progenitor cells,definedbythe co-expression of endothelial and immaturity cell surfacemoleculesand also by the ability to form colonies in vitro.Althoughincreasednumbers of CECs correlate with other markersofvascular disease,questionsremain regarding theprecise definition, cell biology and origin of CECs. Forexample,theymay be damaged, necrotic or apopototic,or alive,and could possess procoagulant and/or proinflammatory Keywords Circulating endothelialc ells,von Willebrand factor,E-selectin, tissue factor,CD146
Introduction
The last twenty years have demonstrated unequivocally that well-maintainede ndothelial function and integrity is of undoubtedi mportancei nn umerous conditions, including infectious,neoplastic,inflammatoryand cardiovasculardiseaseand its risk factors. One approach to the assessmento fe ndothelial functioning is changes in specific plasma markers such as von Willebrand factor,soluble thrombomodulin, tissue plasminogen activator,s oluble endothelial cell protein Cr eceptor (sEPCR) and soluble Es electin: anotheri sb yp hysiological techniques suchasflowmediated dilatation after reactivehyperaemia (1, 2) . More recently, an additionalmethodfor assessing vascularintegrity has beendeveloped: the measurement of immunologicallydefined circulating endothelial cells (CECs) in the peripheral blood (3) .These cells arethought to originate from sloughing off the vesselwallfollowing some formofpathological insult. They are definedp henotypicallyb yt he expression of endothelial markers (e.g.v on Willebrand factor,VE-cadherin, CD146) together withthe absence of the expression of leukocyte (CD45) and immaturity markers (CD133).
Morerecently,another population of cells in the blood (often designated as circulating endothelial progenitor cells (EPCs) ) have beendescribed thatare believedtoarise notfrom the vessel wall butfrom the bonemarrow, and to be important in repairfollowing vasculardamage. Definedvariouslybythe co-expression of immaturity (e.g. CD34, CD133) and 'mature'e ndothelial markers (von Willebrand factor,VE-cadherin), and an ability to formcolonies in vitro ,EPCs mayalso contribute to angiogenesis and could be physiological replacementsfor replacedead,effete or damaged muralendothelial cells (4, 5) .
The objective of this communication is to summarise the current status of CECsinterms of cellbiology and its translation to clinical medicine.A lthough there is clearlys ome degree of commonality in howd ifferent investigatorsd efine CECs, there is also diversity in technique thatleads to difficulty in comparing data betweensuch groups. To achievethis we conducted al iterature studyi nP ubMed,M edline and Ebaset oi dentify published work with keyw ords circulating endothelial cells. Whilst acknowledgingthe advances brought by work in animal models, we shall focus primarily on human data on CECs. The communication will close with as hortc omparison of CECs and EPCs.
Historical perspective
The undoubted pioneers, Bouvier,G aynor and Hladoveca nd their colleagues, initiallyd efinedC ECs over 30 years ago by techniquessuch as vital light microscopyusing morphology and Giemsa staining,and separation by Ficolldensity centrifugation (6) (7) (8) . Animalmodels showedthat damage or shock by E. Coli endotoxin,o valbumin or trisodium citrater esults in increased numbers of CECs,w hich, in the case of the latter,w ere frequently reported to be without anucleus (7) (8) (9) .Subsequent work in humans demonstrated changes in CECs in smoking, acute myocardiali nfarction, immunosuppression, hypertension and homocysteinaemia after methionine load,again some reporting CECs to be anucleatec arcasses (10) (11) (12) (13) (14) . Othersd efinede ndothelial cells isolatedf rom blood by indirect immunofluoresence with antibodiestovon Willebrand factor,anintracellular molecule that is gaining acceptance as am arker of this cell (15) (16) (17) . However, poor specificity of these varioustechniques hamperedresearch in this area and highlightedthe needfor areliable, endothelial-specificc ells urfacem olecule that could be used as an appropriate tool. Potentialcandidateswere eithernonspecific for the endothelium (e.g. adhesion molecules, integrins) or were intra-cellular( e.g.t issue plasminogena ctivator,v on Willebrand factor)and therefore relatively inaccessible to monoclonal antibodies, without cellpermeabilization.
Simultaneously,i n1 991, twog roups reported monoclonal antibodiestonew cellsurfaceantigens on endothelial cells (HEC 19 and S-Endo 1) and used them to quantify blood-borne CECs (18, 19) . Dignat-George and colleagues subsequentlycharacterised their antibody (20, 21) as recognizing the CD146 molecule and used it to demonstrate CECsi navariety of conditions including rickettsial infection, sickle celld isease, thrombotic thrombocytopenia and acutecoronary syndromes (3, (24) (25) (26) . In 1997, Solovey et al.also usedamonoclonalantibody (P1H12) against CD146 (22) to detect CECsinsickle cellanaemia (23) . Morerecently,variousgroups have reported increased numbers of CECs in many diverse diseases, situations and conditions including infectious and cardiovasculard isease, cancer,a nd inflammatoryc onnective tissue disease . However, these reportsare diverse notonlywith regard to the diseasestudiedbut also in the precise methods of isolation and detection employed. Not surprisingly, these technical variationsi mpact on the number of CECs detected.
Methodological issuesinCEC quantification
In practice, oneofthe major problems in clinicalstudieswith the quantification of CECs are the lownumberspresentinthe blood (Gaynor et al. suggests af requencyo fa pproximatelyo ne per million nucleatedc ells (47)) .H owever,i mproved detection of these rare eventscan be achieved by combining cellenrichment techniques with labelling of the cells with aspecific marker. Different groups have used varioustechniquesinthe pursuit of cell enrichment, such as the elimination of redblood cells and con- Due to the diversity of each of these diseases and methods, there is variability in the levels of CECs reported in diseasestates ranging from an averageof1to 39,000 cells/ml of whole blood. Someofthis variance can clearlybeascribedtothe diverse disease processes in operation.H owever,o fm ore concerni st he wide variation of CECs in those supposedlyh ealthyc ontrols, ranging from zero to 7,900 cells/ml.Thereisagreater degree of agreement in thoseusing the immunobead method (19,24-27, 36, 38, 39, 42) and density centrifugation (32, 34, 37, 40) , with valuesinthe orderof10cells/ml, whereas flow cytometryseems moresensitive,often reporting greater numbers, up to 1000-fold higher than the immunobeadmethod (33, 45, 46) .
Numerous groups have used the immunobeadc apture method initiallyd eveloped by Dignat-George et al. (Table 3 ). The method has been slightly modifiedbyothers, e.g.the addition of albumin and EDTAasacountermeasure to minimisethe auto-aggregation of CECs (23) , bringing CECs to aglass slide and airdrying before counting (a method thatallows storage at room temperature for latercounting as well as second-labelling) (42) , and the use of the plant lectin UlexEuropeus-1 to aid positive identification (48)with use of aF c blocking agent to minimise non-specific binding by leucocytes (36, 38, 44) . Immunobead-generatedCECs canalso be double-labelledfor other analyses, e.g.for CD133, CD34, or adhesion molecules(Table1).
Them ost common alternative to the CD146/immunobead method is flow cytometry( am ethodu sedf or EPC determination, seelater in this document),wherewhole blood is generallyl abelledw ith monoclonal antibodiest agged with fluorochromes (33, 45, 46 ). An advantage of this technique is rapid multiparametric analysis, and the ability to detect sub-populations, suchas'bright'versus'dim' labelling (34) ,and activated (e.g.b earing CD106) or resting (45) , although( as discussed) CECs purified by the immunobead method can also be double labelled. However, there are substantiald ifferences between the twomethods,asindicated by the high variation in levels of CECs of healthycontrols (Table 2 ). These differencesmay be secondaryt oi solation procedure, where ah igh erroro fm easurement mayexist due to inadequate standardization of flowconditions. Forexample, the gating of the forward and side scatteraswellas the threshold maycollect measurements not onlyfor intact circulating endothelial cells buta lso aggregateso fl eukocyte-endothelial cells as well as endothelialcellmicroparticles. Thefluorescence measurementsw ill be difficultt oi nterprets incea consequenceo ft he choiceo fg ating is thatm easurementsi nclude manynon-CECs.
It is clear from the above thatCD146 is one of themost popular,ifnot the most popular,choice of amarker forCECs.However,this molecule has also beendescribed on trophoblast, mesenchymal stem cells, periodontaltissue and malignant (prostatic cancer,melanoma)tissues (49) (50) (51) , so that some caution is demanded, especially in cancer.
Where do CECs come from andhow do theyappear?
Perusalofthe listofdiseases and conditions in table2supports the conclusion that the majority areassociatedwith asevere and injurious pathology.I ts eemsr easonable,t herefore,t hat increased CECsnumbersinthe blood arethe productofadisease process that irreversiblydamages the endothelium. This theoryis intrinsically attractive, giventhe knowledge of the pathophysiologyofconditions in whichCECs were found,such as established vasculardamage in cardiovasculardisease, the 'response to injury' theoryofatherosclerosis (52) , and the widespreadvasculopathy of inflammatoryconnective tissuesand infectious diseases (24, 32, 34, 38) .
Solovey et al. ( 23) reported that about half of the CECsi n healthycontrols expressed CD36 (i.e.were of microvascularorigin (53, 54) ), afigurerising to 78% in patients with sickle cell anaemia.M utin et al. (26) found no CECsf rom patients with acutecoronary syndromesstainedfor CD36, indicating amacrovascularorigin. Mutungaetal. (32)w ere able to cultureCECs from sixo ffifteen patients with septic shock, proving at least some CECs to be viable. Linetal. have also showedthat vessel- 1 Methods: IB =immunobeads; DC =density centrifugation, SC =standardcentrifugation, FC =flow cytometry. 2 As the distributionofCECs is oftennon-normal, median number is appropriate although some reportthe mean. 3 Stableorcrisis sickle cell disease. 4 Controlsare patients with inactivedisease. 5 Dependent on being restingoractivated. 6 Highest in acute rejection. 7 Rawdata not supplied, therefore estimatedfromafigure. 8 Highest in criticallimb ischaemia. 9 Highest after pretransplantation conditioning. (34, 46) .
Thep otential mechanisms of endothelial cell detachment from the vessels are multiple and notexclusive.Different experimental models have documented that denudation of the vessels can be triggered by mechanical injury, defective adhesivepropertiesofthe endothelial cells,protease or cytokinemediated detachment,orthe activation of an apoptotic program Regarding defectivea dhesion, particular interest has been devotedtothe role of endothelial adhesive molecules belonging to the integrin familythat allowadhesion to matrix components such as vitronectin and fibronectin (57, 58) and also to the cadherin family, especially VE cadherin involved in the control of monolayerintegrity (59) . These molecules promotethe assembly of cytoskeletal proteins and mediate signalscritical forcellsurvival. Loss of the survivalsignals derivedfrom anchorage to the extracellularmatrixcan triggerapoptosis (60) .
Excessive detachment of the endothelium during CMV infection has beenlinked with the absence of expression of the integrin avb3 on CEC isolated in vivo (61) . In vivo experiments also showeddefectivebindingofinfectedcells to anchoring matrix proteins sucha sfibronectin, laminin, or type IV collagen (62) . These effects mayresultinboth excessive endothelialdetachment and impaired vascularrepairinHerpes Simplexvirus infection. In the same clinical setting proteases released by granulocyteswere also found to causemore detachment of the virally infected cells reported to be especially susceptible to inflammatorycells (62) . It wasrecently reported thatthe integrin avb3 is involved in tumourECdetachment induced by TNF and IFN (57) . In vitro ,e xposure of EC to these cytokines results in reduced activation of integrin avb3, leading to decreasedavb3-dependent EC adhesion and survival. Detachment and apoptosis of EC wasa lso evidenced in vivo, in melanoma metastasis of patients treated by TNF and IFN.These resultsdemonstrate anew mechanism by whichcytokines control cell adhesion. Recently, Clancye ta l. suggestedt hat nitric oxide (NO) mayi ntroducea defecti na dhesive propertyo fe ndothelial cells.N O( via peroxynitrite) acts to decrease the affinity of a5b1 integrin for its matrix ligand,which resultsinanincreased levelofCEC in SLE (34, 63) .
Relationships between CECs and other markers of vascular damage
Numerous epidemiological studieshaveshown that increased levels of plasma markers such as vonW illebrand factor,t issue plasminogenactivator,and,toalesserextent, soluble Eselectin, suggest some degree of disturbance of the endothelium, be it damage,dysfunction or activation, and also indicateadverse cardiovascularoutcome (1, 2, 64-66). More recently, impaired flow mediateddilation (FMD)has also been used to define endothelialdysfunction (67, 68) , and as predicted,thereisaninverserelationship between vonWillebrand factor and FMD (69) . Therefore, if increased numbers of CECs do indeed reflect adamaged endothelium, suchlevelsshould correlate with plasma markers and with FMD.Indeed, Rajagopalanetal. (46) Willebrand factor (p=0.002), and also with plasma tissue factor (p=0.02).S incev on Willebrand factor is essentiallyt he gold standard plasma markerfor endothelial damage (2, (64) (65) (66) , this stronglyindicates that CECsalso reflect severe vasculardisturbance. Del Papa correlated numberso ft otal and activated( i.e. CD62 + CD106 + )CECs withsoluble Eselectin, whilst Rajagopalanetal. (46)correlated CD146 + /Annexin V + CECs withplasma tissue factor,although this pro-coagulant mayarise from monocytes/macrophages as well as fromthe endothelium (70) .
Moreover, if we presume that CECsappearinthe blood as the result of one or more pathologicalprocesses thenwewould also expectfurther evidenceofvascular perturbance, suchasthe releaseo fm icroparticlesb ya ctivatedo ra popototice ndothelial cells.T hese arek nown to be biologicallya ctivei np romoting thrombosis (71), and apoptotic endothelialc ells are procoagu- 1. The subject is venesectedfromanante-cubitalvein: the first 4ml(e.g. avacutainer) arediscarded as it maycontain muralECs removedbytrauma.
2. Astock solution of immunomagnetic beads (diameter 4.5 μ M) coatedwith anti-CD146 antibody is prepared by mixing 100 μ lAnti-CD146 mAb (Biocytex, Marseille,France)with 125 μ lDynabead at 4 x10 8 beads/ml (themselves coatedwith an anti-panmouse IgG)(Dynal Biotech ASA,Oslo,Norway) at room temperaturefor 30 min. Unbound CD146 is washedoff with three washeswith PBS and the stock coated beads arestored at 4 o C.
3. Fifteen μ lfromapreparation of 7x10 7 immunobeads/μl aremixed with venous blood diluted1ml with 3mlinPBS in ahead-over-head mixerfor 30 min, at 4°C. 
Relationships between CECs and activity/ severityofdifferent diseases
Numerous studies in thel iterature have documented that increased numberso fC ECs (bya lmost anyd efinition)c orrelate with, and thus have common ground with, disease severity,asassessedbystandard clinical methods.
In cardiovascular disease, the group of Dignat-George et al. (26) concluded that the highest numbersofCECs arefound in the blood of subjects with the most severe and acutecoronary artery disease. More recently, theydemonstrated thatCEC count, combined withtroponin level, can be used as an early, specific, independent diagnostic marker for non-STelevation ACS (73) . Similarly,Makinetal. (42)found the highest CECsinthose patients with the most severe peripheral artery disease whilst Bull et al. (40) and DelPapa et al. (45) reported acorrelation between pulmonarya rteryb lood pressurea nd CEC number.This relationship mayb ed ue to the high blood pressure damaging and thus converting mural endothelialc ells into CECs. Notably, it hasb een establishedt hat the plasma markero fe ndothelial damage,von Willebrand factor,israisedinhypertension (74) (75) (76) .
In the fieldoftransplantation,Popa et al. (35) concluded that the appearanceofdonor CECswas duetopost-transplantational injury. Morer ecently,W oywodt et al. (44) showede levated numbersofCECs in patientsbeing pre-conditionedfor allogeneic bone marrowtransplantation,with lowercellnumbersafter reduced-intensity conditioning. Alikelye xplanation is that the conditioning regime is such an insultt ot he vasculart ree that mural endothelialc ells are peeled offt he intima to become CECs.
In inflammatorya nd connective tissue diseases,D ignatGeorge et al.r eported the highestC EC levels in patients with malignant forms of Mediterranean spottedfever (24) .W oywodt et al. reported (38) astrong correlation (r=0.704, p<0.001)between CEC numbera nd the severity of diseasei n8 6p atients with inflammatoryvasculitis. In systemicsclerosis, DelPapa et al. (45) reported that total and activatedCEC counts were positively correlated with the diseaseactivity score. In SLE, aprototypic autoimmune condition in whichcirculating immune complexesa re likelyi nvolved in endothelial stimulation and shedding, patients with active disease expressed significantly higher levels of CECs in peripheral blood comparedtopatients with inactivediseaseorhealthycontrols (34) .Asexpected,the levels of CECs correlated positively withc omplement activation as assessedb yplasma C3a.Furthermore,CECs from these patients expressed an activatedphenotype as indicatedbystaining for nitrotyrosine, aproxy of the inflammatorymediator,peroxynitrite (34) .
In cancer,the generation of newblood vessels, angiogenesis, is crucial in tumourgrowthand metastasis; the endothelium is centraltothis process (77) .Indeed, as newclassesofdrugs with targetedactivity on angiogenic vessels have beendeveloped to control cancer progression (78,7 9) , assessment of endothelial function is crucial. In breast cancera nd lymphoma patients, CECs were increased 5-fold (p<0.0008v s. control) and correlated significantly withp lasma VCAM-1a nd VEGF. CECs were similartohealthycontrols in 7lymphoma patients achieving complete remission after chemotherapy (33) . Repeated CEC measurementsinpatients and controls indicated alow longitudinalCEC variation,and the count of resting and activatedCECs did not correlate withthe count of white cells, red cellsorplatelets.
To date,the origin of these CECs(tumourand/or its vessels, normal endothelium or bonemarrow) is unclear butisobviously must be determinedasitmay have abearing on tumourbiology (e.g.reflectiveornot of newvesseldevelopment?). Forexample, the correlation betweenCECs and VEGF (r=0.42) mayimplya relationship with angiogenesis, although about halfofCECs expressed CD36, implying amicrovascularorigin. However, there wasnodifference in CEC countsinearlyversus metastatic breast cancer.Otherdatafrom patients with cancer is urgentlyrequired.
Implications of CECs forthrombosis and haemostasis
As endothelial cells are dynamicparticipants in the homeostasis of coagulopathy and hypertension, their loss from the intima seems likelytohaveimportant repercussions (1) . It follows that CECsthemselves mayparticipate in pathology.V ariousgroups have performed additional characterisation of the CECsinwhich moleculescontributing to the balance of coagulation of inflammation have beenevaluated. Forexample, Dignat-George et al. (19) reported CECspositivefor thrombomodulin, butwhetheror not this molecule is still bio-active is unclear.Solovey et al. (80) showedi nC ECs in sickle cell disease the expression of tissue factor thatisfunctionallyactive. SomeCECs reported by Mutin et al. ( 26) were alsot issue factor positive,F urthermore,t hese CECsw ere nota poptotic( as definedb yt he TUNEL assay). CECsf rom patients with small vesselv asculitis stainedp redominantlyfor tissue factor,suggesting aprothrombotic potential; allw ere TUNELa ssayn egative, and most (84%) stained with annexin and propidium, suggesting necrosis (38) .However, although many groups have found tissue factor positivity, whether or notthis is clinicallyimportant in promotingthrombosis is unknown.
With regard to molecules regulating leukocyte endothelial adhesion, half of the CECs isolatedfrom patients with thalassaemia expressed ICAM, E-selectin and VCAM (37),w hilsta pproximatelyt wo thirds of the CECs in sickle celld iseasea nalysedbySolovey et al. (23) also expressed these adhesion molecules, suggesting an activatedstate (23) . ActivatedCECs,defined as VCAM-1 and E-selectin positivity by Del Papa et al., were higher in patients with systemic sclerosis (45) .
At the interface between coagulation and inflammation, the endothelialcellprotein Creceptor (EPCR) is acell-surface protein with important roles, such as inhibition of thrombosis (81) . Ac onsequence of stimulation is the shedding of membrane EPCRwhich would be expected to have anegativeimpact on the delicateb alance of coagulation and inflammation (82) . Increased levels of solubleEPCR were recently noted in the plasma of patients with SLE, particularly thosew ith renal disease, as well as avariable expression of membrane EPCRonCECs from SLEpatients. However, in the controls, levels were lower (83) .
Thus the absence of membrane EPCRonCECs further supports aprocoagulant state as the thrombin-thrombomodulin-dependent proteinCactivation is attenuatedand functionallyinvolves a loss of a'brake'tothrombosis (84) .
CECs andEPCs
Endothelial progenitor cellsare acirculating, bone-marrow-derivedcellpopulation of large non-leukocyte cells that appear to participate in vascularrepairand homeostasis. From atheoreticalpoint of view, the keyfeatures thatseparateCECs from EPCs areorigin(vasculature vs. bone marrow),phenotype,morphology, and proliferativec apacities. An umber of characteristic propertieso fE PCs have beenp roposed,n otably positivity for CD34 (marking haematopoietic progenitor cells),CD133 (a putativelymore specific markerofEPCs) and KDR,the receptor for vascularendothelial growth factor (5, 52, (85) (86) (87) (88) (89) (90) (91) (92) (93) . Other surface markers of EPCs are UEA-1,which is also present on CECs, and Tie-2.T he dominant determining methodsa re flow cytometrya nd culture,w herebyu ptakeo fa cetylated LDLi so ften used to proveendothelial lineage of outgrowing cells.The general thrust of the literatureisthat bone marrowderivedEPCs are viable and capable of promotingendothelialisation: indeedseveral groups raise colonies in vitro from CD34 + cells thatr esemble matureendothelial cells (5, 86, 87, 91) . Lin et al. generated endothelialoutgrowths from peripheral blood mononuclear cells thatwere subsequentlypositivefor CD146, vonWillebrand factor and,c rucially,C D36, supporting am icrovascularo rigin for this population (53) (54) (55) . TheimportanceofEPCs as anew therapyinvascular diseasehas been emphasized elsewhere (92, 93) .
However, giventhe variety of defining markers (Table 1) ,a good consensus of howt od istinguish CECs from EPCs is, at best, difficult. Forexample, Mutungaetal. (32)use vonWillebrand factor and KDR to define CECsfrom patients with septic shock, subsequentlyc ulturing cells from 6o f1 5p atients. Between 70%and 90% of these cells were positive for vonWillebrand factor,K DR (thus,a ccording to the authors,e xcluding other circulating haempoietic cells)a nd endoglin. There is indeedconsiderablescopefor the dual identification of CECsand EPCs. Fore xample, Nakatani et al. (39) used P1H12-immuno beads to isolate CECs, and AC133 to define EPCs, concluding that EPCsare asub-population of CECsand that the twopopulations have different timecourses. DelPapa et al. (45) used flow cytometrytodefine CECs as CD45 -,CD34 + ,and P1H12 + (additionallydefining activation by CD62 [the authors do notstate the precise molecule,and although we presume CD62E, it could be CD62P]and CD106), EPCsasCD34 + and CD133 + .Insummary, the liberal useofdefinitionsand antigens has caused some confusion, and progressinCEC and EPCresearch will not advance until aconsensus has beenreached.
Most groups working on CECs first capture cellsw ith CD146-immunobeads and thenperform additionalphenotyping, e.g. for markers of activation. Others preparemononuclear cells by density centrifugation then stain for CD146. These studies generallyfailt oa ddress the question of the viabilityo fC ECs: one that does (from sickle cell disease, [80] )r eportst hat two thirds are viable.Another study in vasculitis using CD146-dependent immunobeadi solation demonstrated am ajority of necrotic cells with no growth in culture (38) . Hence,this study suggests that CD 146-dependent immunobeadi solation doesn ot isolate relevant numberso fE PCs sincet hese cells would have proliferated well. It has been demonstrated previouslyt hat the isolation procedureitself doesnot affect apoptosis or necrosis in endothelial cells (38) .However,ithas been proposed thatEPCs or even pericytesmay be CD146-positive,suggesting that capture of those cells maystill occur (94) .Consistent with this hypothesis, Burger et al reported the expression of CD146 on CD34+/FGFR1+ circulating cells yielding small round cells with lowg rowthp otential when cultured (4). However, in another study,W oywodt et al. (44) were unable to find any CD146-immunobead prepared CECs thatstainedfor AC133 or alpha-smooth-muscle-actin, thus minimising the likelihood that these cells areEPC or pericytes. Finally, CECs are oftenseen in morphologies(irregularcarcasses, clumped cells or even sheets, filamentousc ellr emnants) thatd iffer markedlyf rom thato f EPCs.T aken together, although until nowthereisnoclear evidencet hat CD146-dependent isolation does not significantly captureEPCs, thepossibilitythat CD146 identifies some EPCs in addition to CECs needs further investigation.
In summary,t he common viewi se merging thatC ECs and EPCs areindeedseparatepopulations. The former represent mature endothelial cells shed from the vesselwallinresponsetoa damaging stimulus,while the latter areprogenitor cells derived from bone marrow.EPCs bear endothelialmarkers and (at least) CD34and CD133 while CECs lack CD133. Aformal consensus in this regard can be seen in table4,which summarises characteristic features of CECs as opposedtoEPCs.
Conclusions
It is clear thati ncreased numberso fC ECs arep resenti nt he blood of patients with awide variety of clinical diseases linked by ahistoryofvascular injury. Their presence implies severe vascular damage, afeaturethat other vascularfunction tests (plasma markers such as vonWillebrand factor,flowmediatedilatation) cannot offer with suchc onfidence. The enumeration of CEC mayprovide useful information in the monitoring of diseaseactivity and/or treatment efficacy. Indeed,t herea re reportsf rom twodifferent groups that high levels of CECs maybeanovelpredictorofadverse cardiovascularevents in patients with acute coronarysyndromes (73, 95) . In one of these studies (95) ,the predictive powero fC ECs exceeded thato fp lasma marker von Willebrand factor.However,the absence of auniformmeasureof quantitation to ensurec omparable reproducible results, especiallyb etween immunomagnetic isolation and flow cytometry, is ad rawback.A lthough there is ag rowing belieft hat CEC canb ec onsidereda ni ndicator of endothelial injury, it is vitaltoreach ageneral consensus regarding the most appropriate technique in ordertovalidate the reporting of CECs in largecohorts of patients. This validation hascritical implications on futureclinical trials in whichCECs might function as anovel biomarker and perhapsasasurrogate endpoint.
